Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB | SpringerLink
Real-world use of ACEI/ARB in diabetic hypertensive patients before the initial diagnosis of obstructive coronary artery disease: patient characteristics and long-term follow-up outcome | Journal of Translational Medicine | Full Text
Effect of Angiotensin II Inhibitors on Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices - ScienceDirect
Impact of renin–angiotensin–aldosterone system inhibitors on COVID-19 | Hypertension Research
Therapeutics Initiative | How do you prescribe ACEIs and ARBs for hypertension?
ACE inhibitors and ARBs: Managing potassium and renal function | Cleveland Clinic Journal of Medicine
Frontiers | The effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in critically ill patients with acute kidney injury: An observational study using the MIMIC database
From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) - ScienceDirect
ARB might be superior to ACEI for treatment of hypertensive COVID‐19 patients - Zhao - 2021 - Journal of Cellular and Molecular Medicine - Wiley Online Library
Side Effects of ACEi/ARBs During Pregnancy | Calgary Guide
Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension – An Update of the 2007 Report | Effective Health Care (EHC) Program
Angiotensin converting enzyme inhibitors and incidence of lung cancer in a population based cohort of common data model in Korea | Scientific Reports
Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers in COVID-19 - The Centre for Evidence-Based Medicine
COVID-19 and Use of Drugs Targeting the Renin-Angiotensin-System - American College of Cardiology
Prevention of renal failure in Chinese patients with newly diagnosed type 2 diabetes: A cost‐effectiveness analysis - Wu - 2018 - Journal of Diabetes Investigation - Wiley Online Library
JCM | Free Full-Text | Angiotensin-Inhibiting Drugs Do Not Impact Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Cross-Sectional Study
Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers in COVID-19 - The Centre for Evidence-Based Medicine
Cross-Reactivity of ACE Inhibitor–Induced Angioedema with ARBs
SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy - eBioMedicine
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial - The Lancet Respiratory Medicine
Cureus | Comparison Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Incidence of Lung Cancer: A Retrospective Study | Article
Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension? | SpringerLink
Frontiers | Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitor in Combination with Angiotensin-Receptor Blocker in Chronic Kidney Disease Based on Dose: A Systematic Review and Meta-Analysis
FDA Advise-ERR: Concomitant use of Entresto and ACE inhibitors Can Lead to Serious Outcomes | Institute For Safe Medication Practices
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research
Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients | eLife
There's just been AKI. So what do we do with the ACEi/ARB? — NephJC
